Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Cooper

Showing results (301-310 of 324) with videos related to

Pageof 33
Sort By:
The Journal of Infectious Diseases|February 16, 2010
Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infectionDavid A Cooper, Jayvant Heera, James Goodrich, et al.
Journal of Virology|May 22, 2009
Impaired quality of the hepatitis B virus (HBV)-specific T-cell response in human immunodeficiency virus type 1-HBV coinfectionJ Judy Chang, Sunee Sirivichayakul, Anchalee Avihingsanon, et al.
The Lancet. Infectious Diseases|May 14, 2013
Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trialsJoseph J Eron, David A Cooper, Roy T Steigbigel, et al.
Nature Communications|October 10, 2015
Immunological biomarkers predict HIV-1 viral rebound after treatment interruptionJacob Hurst, Matthias Hoffmann, Matthew Pace, et al.
The New England Journal of Medicine|October 4, 2008
Subgroup analyses of maraviroc in previously treated R5 HIV-1 infectionGerd Fätkenheuer, Mark Nelson, Adriano Lazzarin, et al.
The Lancet. HIV|July 30, 2016
Low-dose versus standard-dose ritonavir-boosted atazanavir in virologically suppressed Thai adults with HIV (LASA): a randomised, open-label, non-inferiority trialTorsak Bunupuradah, Sasisopin Kiertiburanakul, Anchalee Avihingsanon, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 30, 2007
Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005Bruno Hoen, David A Cooper, Fiona C Lampe, et al.
The Lancet. HIV|July 21, 2018
Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort studyBenjamin R Bavinton, Angie N Pinto, Nittaya Phanuphak, et al.
JAMA|July 4, 2002
Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA PanelPatrick G Yeni, Scott M Hammer, Charles C J Carpenter, et al.
Lancet (London, England)|January 16, 2010
Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trialsJoseph J Eron, Benjamin Young, David A Cooper, et al.
Pageof 33

Showing results (301-310 of 324) with videos related to

Sort By:
Pageof 33
The Journal of Infectious Diseases|February 16, 2010
Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infectionDavid A Cooper, Jayvant Heera, James Goodrich, et al.
Journal of Virology|May 22, 2009
Impaired quality of the hepatitis B virus (HBV)-specific T-cell response in human immunodeficiency virus type 1-HBV coinfectionJ Judy Chang, Sunee Sirivichayakul, Anchalee Avihingsanon, et al.
The Lancet. Infectious Diseases|May 14, 2013
Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trialsJoseph J Eron, David A Cooper, Roy T Steigbigel, et al.
Nature Communications|October 10, 2015
Immunological biomarkers predict HIV-1 viral rebound after treatment interruptionJacob Hurst, Matthias Hoffmann, Matthew Pace, et al.
The New England Journal of Medicine|October 4, 2008
Subgroup analyses of maraviroc in previously treated R5 HIV-1 infectionGerd Fätkenheuer, Mark Nelson, Adriano Lazzarin, et al.
The Lancet. HIV|July 30, 2016
Low-dose versus standard-dose ritonavir-boosted atazanavir in virologically suppressed Thai adults with HIV (LASA): a randomised, open-label, non-inferiority trialTorsak Bunupuradah, Sasisopin Kiertiburanakul, Anchalee Avihingsanon, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 30, 2007
Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005Bruno Hoen, David A Cooper, Fiona C Lampe, et al.
The Lancet. HIV|July 21, 2018
Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort studyBenjamin R Bavinton, Angie N Pinto, Nittaya Phanuphak, et al.
JAMA|July 4, 2002
Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA PanelPatrick G Yeni, Scott M Hammer, Charles C J Carpenter, et al.
Lancet (London, England)|January 16, 2010
Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trialsJoseph J Eron, Benjamin Young, David A Cooper, et al.
Pageof 33